For research use only
| Cat No. | ABC-X0319C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human HRAS (G12A) BAF3 Cell Line enables studies on HRAS-driven oncogenesis and its influence on signal transduction and anti-cancer drug responses.
Human HRAS (G12A) BAF3 Overexpression Cell Line is developed from murine Ba/F3 cells by stably integrating a lentiviral construct expressing HRAS with the G12A point mutation. Expression is confirmed by qRT-PCR and cells are maintained at early passages (<P20). Target HRAS is a proto-oncogene encoding a GTPase involved in mitogenic signaling. The G12A mutation enhances HRAS activity by reducing GTP hydrolysis, contributing to oncogenic transformation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0319C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This engineered cell line facilitates the dissection of HRAS-mediated oncogenesis and drug discovery targeting aberrant RAS/MAPK signaling cascades in cancer models.